Journal of Clinical Epidemiology
Volume 54, Issue 1 , Pages 51-57 , January 2001

Prospective association of lipoprotein(a) concentrations and apo(a) size with coronary heart disease among men in the Multiple Risk Factor Intervention Trial

  • Rhobert W Evans

      Affiliations

    • Both authors contributed equally.
    • Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15261, USA
    • Corresponding Author InformationCorresponding author
    • ,
  • Ofer Shpilberg

      Affiliations

    • Both authors contributed equally.
    • Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15261, USA
    • ,
  • B.Jessica Shaten

      Affiliations

    • MRFIT Coordinating Center, Division of Biostatistics, University of Minnesota, Minneapolis, MN 55414-3080, USA
    • ,
  • Shabnam Ali

      Affiliations

    • Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA 15261, USA
    • ,
  • M.Ilyas Kamboh

      Affiliations

    • Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA 15261, USA
    • ,
  • Lewis H Kuller

      Affiliations

    • Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15261, USA

Received 5 January 1999 ,Revised 4 April 2000 ,Accepted 12 April 2000.

References 

  1. Berg K. A new serum type system in man (the Lp system). Acta Pathol Microbiol Scand. 1963;59:369–382
  2. Scanu AM, Fless GM. Lipoprotein(a) (heterogeneity and biological relevance). J Clin Invest. 1990;85:1709–1715
  3. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132
  4. Scanu AM. Lipoprotein(a). A potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med. 1988;112:1045–1047
  5. Loscalzo J. Lipoprotein(a) (a unique risk factor for atherothrombotic disease). Arteriosclerosis. 1990;10:672–679
  6. Marcovina SM, Morrisett JD. Structure and metabolism of lipoprotein(a). Curr Opin Lipid. 1995;6:136–145
  7. Levitsky LL, Scanu AM, Gould SH. Lipoprotein(a) levels in black and white children and adolescents with IDDM. Diabetes Care. 1991;14:203–207
  8. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csaszar A, et al. Effects of the apolipoprotein (a) size polymorphism on the lipoprotein (a) concentration in seven ethnic groups. Human Genet. 1991;86:607–614
  9. Srinivasan SR, Dahlen GH, Jarpa RA, Webber LS, Berenson GS. Racial (black–white) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children. Bogalusa Heart Study. Circulation. 1991;84:160–167
  10. Multiple Risk Factor Intervention Trial Research Group . Multiple risk factor intervention trial (risk factor changes and mortality results). JAMA. 1982;248:1465–1477
  11. Kuller LH, Tracy RP, Shaten J, Meilahn EN for the MRFIT Research Group . Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 1996;144:537–547
  12. Usher DC, Swanson C, Rader DJ, Kramer J, Brewer HB. A Comparison of Lp(a) levels in fresh and frozen plasma using ELISAs with either anti-apo(a) or anti-apoB reporting antibodies. Chem Phys Lipids. 1994;467(68):243–248
  13. Utermann G, Menzel HJ, Kraft HG, Daba HC, Kemmler HG, Seits C. Lp(a) glycoprotein phenotypes (inheritance and relation to Lp(a) lipoprotein concentrations in plasma). J Clin Invest. 1987;280:458–465
  14. Taddei-Peters WC, Butman BT, Jones GR, Venetta TM, Macomber PF, Ransom JH. Quantification of lipoprotein(a) particles containing various apolipoprotein(a) isoforms by a monoclonal anti-apo(a) capture antibody and a polyclonal anti-apolipoprotein B detection antibody sandwich enzyme immunoassay for Lp(a). Clin Chem. 1993;39:1382–1389
  15. Kamboh MI, Ferrell RE, Kottke B. Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet. 1991;49:1063–1074
  16. Craig WY, Poulin SE, Ledue TB, Kamboh MI. Apolipoprotein (a) (a comparison of isoforms identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis or by sodium dodecyl sulfate-agarose gel electrophoresis). Electrophoresis. 1993;14:1038–1041
  17. Caggiula AW, Christakis G, Farrand M, Hulley SB, Johnson R, Lasser NL, et al. The Multiple Risk Factor Intervention trial (MRFIT). IV. Intervention on blood lipids. Prev Med. 1981;10:443–475
  18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:449–502
  19. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of systolic hypertension in the elderly (SHEP) . J Am Med Assoc. 1991;265:3255–3264
  20. Macy E, Hayes T, Tracy R. Variability in the measurement of C-reactive protein in healthy subjects (implications for reference interval and epidemiological applications). Clin Chem. 1997;43:52–58
  21. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D. Apolipoprotein(a), AI and B and parental history in men with early onset ischaemic heart disease. Lancet. 1988;1:1070–1073
  22. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, et al. Lipoprotein(a) and coronary heart disease risk (a nested case-control study of the Helsinki Heart Study Participants). Atherosclerosis. 1991;89:59–67
  23. Haffner SM, Moss SE, Klein BE, Klein R. Lack of association between lipoprotein(a) concentrations and coronary heart disease mortality in diabetes (the Wisconsin Epidemiologic study of diabetic retinopathy). Metabolism. 1992;41:194–197
  24. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195–2199
  25. Alfthan G, Pekkanen J, Jauhianinen M, Pitkaniemi J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9–19
  26. Cantin B, Gagnon F, Moorjani S, Despres JP, Lamarche B, Lupien PJ, et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men?. The Quebec Cardiovascular Study. J Am Coll Cardiol. 1998;31:519–525
  27. Armstrong VW, Cremer P, Eberle E, Marnke A, Schulze F, Wieland H, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis. 1986;62:249–257
  28. Dahlen GH, Guyton JR, Arrar M, Farmer JA, Kautz JA, Gotto AM. Association of level of lipoprotein Lp(a). Plasma lipids and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758–765
  29. Murai A, Miyahara T, Fujimato N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986;59:199–204
  30. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256:2540–2544
  31. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease (a prospective case-control study in a general population sample of middle-aged men). Br Med J. 1990;301:1248–1251
  32. Sandkamp M, Funke H, Schulte H, Kohler E, Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem. 1990;36:20–23
  33. Brown SA, Morrisett JD, Boerwinkle E, Hutchinson R, Patsh W. The relation of lipoprotein(a) concentrations and apolipoprotein(a) phenotypes with asymptomatic atherosclerosis in subjects of the atherosclerosis risk in communities (ARIC) Study. Arterioscler Thromb. 1993;13:1558–1566
  34. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994;271:999–1003
  35. Bostom AG, Gagnon DR, Cupples LA, Wilson PWF, Jenner JL, Ordovas JM, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women—the Framingham Heart Study. Circulation. 1994;90:1688–1695
  36. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PWF, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. JAMA. 1996;276:544–548
  37. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors (results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS)). Eur J Clin Invest. 1994;24:444–453
  38. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol. 1992;69:1251–1254
  39. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford five-city project participants. Arterioscler Thromb Vasc Biol. 1997;17:239–245
  40. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77:1179–1184
  41. Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G. Lipoprotein (a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. Arterioscler Trans Vasc Biol. 1996;16:1568–1572
  42. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease (metanalysis of prospective studies). Clin Chem. 1998;44:2301–2306
  43. Evans RW, Sankey SS, Hauth BA, Sutton-Tyrrell K, Kamboh MI, Kuller LH. Effect of sample storage on quantitation of lipoprotein(a) by an enzyme=linked immunosorbent assay. Lipids. 1997;31:1197–1203
  44. Min WK, Lee JO, Huh JW. Relation between lipoprotein(a) concentrations in patients with acute-phase response and risk analysis for coronary heart disease. Clin Chem. 1997;43(101891–5):
  45. Abe A, Noma A. Studies on apolipoprotein(a) phenotypes. Part 1. Phenotype frequencies in a healthy Japanese population. Atherosclerosis 1992;96(1):1–8.
  46. Farrer M, Game FL, Albers CJ, Neil AW, Winocour PH, Laker MF, et al. Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms. Arterioscler Thromb. 1994;14:1272–1283
  47. Gaubatz JW, Ghanem KI, Guevara J, Nava ML, Patsch W, Morrisett JD. Polymorphic forms of human apolipoprotein(a) (inheritance and relationship of their molecular weights to plasma levels of lipoprotein(a)). Lipid Res. 1990;31:603–613
  48. Gazzaruso C, Buscaglia P, Garzaniti A, Falcone C, Mariotti S, Saviino S, et al. Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension. J Hyperten. 1997;15:227–235
  49. Jürgens G, Taddei-Peters C, Költringer P, Petek W, Chen Q, Joachim G, et al. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke. 1995;26:1841–1848
  50. Kamboh MI, Svitko CM, Williams ER, Ferrell RE, Pollitzer WS. Hypervariable polymorphism of APO(a) in blacks and whites as reflected by phenotyping. Chem Phys Lipids. 1994;67(68):283–292
  51. Kark JD, Sandholzer C, Friedlander Y, Utermann G. Plasma Lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women (a case-control study in the Jerusalem population). Atherosclerosis. 1993;98:139–151
  52. Kraft HG, Dieplinger H, Hoye E, Utermann G. Lp(a) Phenotyping by immunoblotting with polyclonal and monoclonal antibodies. Arteriosclerosis. 1988;8:212–216
  53. Kratzin H, Armstrong VW, Niehaus M, Hilschmann N, Seidel D. Structural relationship of an apolipoprotein(a) phenotype (570 kDa) to plasminogen (homologous kringle domains are linked by carbohydrate-rich regions). Biol Chem Hoppe Seyler. 1987;368:1533–1544
  54. Lemming L, Klausen IC, Hansen PS, Gerdes LU, Faergeman O. Apolipoprotein(a) phenotypes in Danes with and without coronary heart disease. Nutr Metab Cardiovasc Dis. 1995;5:231–236
  55. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, et al. Apo(a) isoforms predict risk for coronary heart disease—a study in six populations. Arterioscler Thromb. 1992;12:1214–1226
  56. Thillet J, Doucet C, Chapman J, Herbeth B, Cohen D, Faure-Delanef L. Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity—evidence from a large population of French centenarians. Atherosclerosis. 1998;136:389–394
  57. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904–910
  58. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson G, Boerwinkle E, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990;322:1494–1499
  59. Islam S, Gutin B, Smith C, Treiber F, Kamboh MI. Association of apolipoprotein(a) phenotypes in children with family history of premature coronary artery disease. Arterioscler Thromb. 1994;14:1609–1616
  60. Moliterno DJ, Jokinen EV, Miserez AR, Lange RA, Willard JE, Boerwinkle E, et al. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol. 1995;15:850–855
  61. Abe A, Noma A, Lee YJ, Yamaguchi H. Studies on apolipoprotein(a) phenotypes. Part 2. Phenotype frequencies and Lp(a) concentrations in different phenotypes in patients with angiographically defined coronary artery diseases. Atherosclerosis 1992;96:9–15.
  62. Parlavecchia M, Pancaldi A, Taramelli R, Valsania P, Galli L, Pozza G, et al. Evidence that apolipoprotein(a) phenotype is a risk factor for coronary artery disease in men <55 years of age. Am J Cardiol. 1994;74:346–351
  63. Amemiya H, Arinami T, Kikuchi S, Yamakawa-Kobayashi K, Li L, Fujiwara H, et al. Apolipoprotein(a) size and pentanucleotide repeat polymorphisms are associated with the degree of atherosclerosis in coronary heart disease. Atherosclerosis. 1996;123:181–191
  64. Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Kronenberg F, Abe A, et al. Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol. 1996;16:713–719
  65. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989;78:145–150
  66. Slunga I, Johnson O, Dahlen GH, Eriksson S. Lipoprotein(a) and acute-phase proteins in acute myocardial infarction. Scand J Clin Lab Invest. 1992;52:95–101
  67. Kuller LH, Eichner JE, Orchard TJ, Grandits GA, McCallum L, Tracy RP. The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial. Epidemiology. 1991;134:1266–1277

PII: S0895-4356(00)00260-2

Journal of Clinical Epidemiology
Volume 54, Issue 1 , Pages 51-57 , January 2001

Article Tools